DRL inks pact with Amgen to market three drugs in India – Feedback

Dr Reddy’s Laboratories (DRL) has expanded its strategic collaboration with US-based independent biotechnology firm Amgen to market and distribute in India three of latter’s medicines, used in the therapy areas of oncology and osteoporosis.

Under the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said today. In 2015, DRL announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval and launch Amgen’s Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India. “It strengthens our constant endeavour to enhance patient’s access to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis,” said MV Ramana, DRL’s Executive Vice President and Head of Emerging markets and India Business.

http://www.business-standard.com/article/pti-stories/drl-inks-pact-with-amgen-to-market-three-drugs-in-india-116091600652_1.html

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *